Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

HealthTree Radio for AML: Margaret Kasner, MD, Thomas Jefferson University

  • Broadcast in Health
HealthTree Podcast for AML

HealthTree Podcast for AML


Follow This Show

If you liked this show, you should follow HealthTree Podcast for AML.

About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target this mutation and even more progress is occurring with newer drugs and various treatment combinations in clinical trials.

Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, will summarize key developments and clinical trials currently underway for FLT3 positive AML. If you have a FLT3 mutation, this episode is definitely for you. 

Thank you to our episode sponsor, Jazz Pharmaceuticals.

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled